CSI Market
Sign In | Register

Alnylam Pharmaceuticals Inc (ALNY) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access ALNY quarterly Cash Flow →
Examining cash flow movements between Alnylam Pharmaceuticals Inc and Dec 31 2021 reveals how Dec 31 2025 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income313.75
Depreciation & amortization55.66
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories8.47
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation348.24
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt42.47
Charge For Four Zero One K Company Stock Match-
Income Tax Expense Benefit Intraperiod Tax Allocation-
Non Cash Gain On Litigation Settlement-
Equity Securities Fv Ni Unrealized Gain Loss-
Equity Securities Fv Ni Gain Loss2.31
Amortization And Interest Accretion Related To Operating Leases-
Increase Decrease In Operating Lease Liability-
Operating Lease Payments Including Prepayment Adjustment-
Non Cash Interest Expense On Sale Of Future Royalties-
Non Cash Interest Expense On Liabilities Related To The Sale Of Future Royalties And Development Funding238.40
Increase Decrease In Contract With Customer Liability-50.64
Income taxes-31.96
Available-for-sale Securities, Gross Realized Gain (Loss), Excluding Other than Temporary Impairments0.00
Increase (Decrease) in Accounts Receivable-359.96
Increase (Decrease) in Accounts Payable and Accrued Liabilities75.07
Increase (Decrease) in Other Accrued Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-117.72
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities524.08
Investing Activities
Capital Expenditures-58.70
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities1,802.26
Payments to Acquire Available-for-sale Securities, Debt-1,305.08
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities-2.15
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities436.33
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-2.41
Long-term debt - borrowings645.69
Long-term debt - repayments-1,154.91
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock250.03
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Payments For Repurchase Of Common Stock For Employee Tax Withholding Obligations-
Proceeds From Sale Of Royalties Interest-
Payments For Transaction Costs Related To Sale Of Future Royalties And Debt-
Purchases Of Capped Calls Related To Convertible Senior Notes-
Payment For Option Indexed To Equity-35.31
Proceeds From Liabilities Related To The Sale Of Future Royalties And Development Funding6.00
Repayment Of Liabilities Related To The Sale Of Future Royalties And Development Funding-14.27
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-305.19
Effect of exchange rate on cash flow34.94
Discontinued operations0.00
Free Cash Flow465.38
Total Cash Flow690.16
4 historic quarters locked

Sign in to unlock the full Alnylam Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Alnylam Pharmaceuticals Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 12, 2026
  • Source: alny-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-26-007497

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License